BURLINGTON, Mass. – March 26, 2014 – Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery disease, today announced that its TVC Imaging System™, a first-in-class dual-modality intravascular imaging system, will be featured in eight scientific posters during the American College of Cardiology’s (ACC) 63rd Annual Scientific Session. The meeting will be held March 29th-31st at the Walter E. Washington Convention Center in Washington, DC.
The TVC Imaging System integrates near-infrared spectroscopy (NIRS) to detect lipid-core plaques, and enhanced intravascular ultrasound (IVUS) to visualize vessel structure, including the presence of plaques and the degree of stenosis (narrowing). The technology can also identify plaques suspected to be vulnerable to rupture, which can cause a fatal coronary blockage.
“We are pleased that original data from our TVC Imaging System will be presented by multiple investigators at this gathering of the world’s leading experts in cardiology,” said Don Southard, president and chief executive officer of Infraredx. “The new findings support the concept that knowledge of lipid-rich plaque and plaque structure obtained from our multimodality system can optimize stenting, while additional data uses our technology to show that lipid-rich plaque occurs at culprit lesions in coronary events. These positive findings have led us to launch three major outcomes trials – the Lipid-Rich Plaque study, Prospect II ABSORB study and the VA NIRS Oracle study -- to test the hypothesis that NIRS-IVUS imaging can detect vulnerable coronary plaques.”
In advance of the ACC meeting, the TVC Imaging System will be discussed in select talks during the Cardiovascular Research Foundation’s Coronary Physiology and Intravascular Imaging Symposium (CPIIS) 2014, taking place on March 27th-28th at the Ronald Reagan Center in Washington, DC.
About The TVC Imaging System™
The TVC Imaging System™ is a first-in-class dual-modality intravascular imaging system that holds the potential to revolutionize the management of coronary artery disease by providing information that is critical for evaluating vessel structure and composition, also known as true vessel characterization. The TVC Imaging System helps interventional cardiologists identify which patients are prone to complications during stenting. The device enables cardiologists to predict the risk of peri-procedural heart attacks by assessing not only the degree of stenosis, but also the presence and extent of lipid-core plaques (LCP).
The device is the only multimodality imaging system to combine both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS). Through IVUS technology, the TVC Imaging System provides clear and relevant information about vessel structure, in real time. The TVC Imaging System is the only device specifically approved in both the U.S. and Europe for the detection of LCPs. NIRS measurements have been made in over 5,000 patients in over 100 hospitals worldwide.
About Infraredx, Inc.
Infraredx, Inc. is a privately-funded medical device company dedicated to helping provide practitioners with the information needed for enhanced clinical decision making in treating coronary artery disease. The company is committed to improving the safety and efficacy of coronary stenting and ultimately serving as part of a strategy to prevent initial coronary events.
Through its TVC Imaging System™, Infraredx is changing the way coronary artery disease is diagnosed and treated. The TVC Imaging System is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback. Founded in 1998, Infraredx is headquartered in Burlington, Mass. For more information, visit www.infraredx.com.